Chandra Vargeese Sells 3,228 Shares of WAVE Life Sciences (NASDAQ:WVE) Stock

WAVE Life Sciences Ltd. (NASDAQ:WVE) insider Chandra Vargeese sold 3,228 shares of WAVE Life Sciences stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $13.45, for a total value of $43,416.60. Following the transaction, the insider owned 408,246 shares in the company, valued at approximately $5,490,908.70. The trade was a 0.78% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

WAVE Life Sciences Stock Down 3.5%

Shares of NASDAQ:WVE opened at $12.80 on Friday. WAVE Life Sciences Ltd. has a 52-week low of $5.28 and a 52-week high of $21.73. The stock has a market cap of $2.14 billion, a P/E ratio of -17.07 and a beta of -1.78. The business has a fifty day moving average of $15.09 and a two-hundred day moving average of $10.39.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.02). WAVE Life Sciences had a negative net margin of 111.64% and a negative return on equity of 75.61%. The firm had revenue of $7.61 million for the quarter, compared to analyst estimates of $9.85 million. On average, equities analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 earnings per share for the current year.

Trending Headlines about WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Wells Fargo kept an “overweight” rating on WVE and set a $27 price target (down from $29), which still implies substantial upside versus the current share price — a signal that some sell‑side analysts remain constructive on the company’s pipeline and long‑term prospects. The Fly: Wells Fargo price target note
• Positive Sentiment: Broader analyst coverage remains favorable — multiple firms have upgraded or raised targets in recent months and the consensus remains skewed toward Buy/Outperform, supporting potential upside if clinical progress continues. MarketBeat analyst roundup
• Neutral Sentiment: Institutional ownership is very high (~90%), which means large holders dominate supply — that can both support the stock during positive news and amplify moves when those holders change positions.
• Negative Sentiment: Multiple insiders sold shares on Feb 9 (CEO Paul Bolno, CFO Kyle Moran, and other officers/directors), executing sizable sales at roughly $13.45 per share — the cluster of top‑executive sales is being viewed negatively by the market as a potential signal of near‑term insider liquidity. InsiderTrades alert
• Negative Sentiment: WAVE’s last reported quarter missed estimates (EPS and revenue) and the company remains unprofitable with wide negative margins — ongoing cash burn and execution risk keep the shares sensitive to clinical and revenue updates. MarketBeat: earnings summary

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on WVE. Raymond James Financial reissued an “outperform” rating and issued a $21.00 price target on shares of WAVE Life Sciences in a research note on Monday, December 8th. Royal Bank Of Canada raised WAVE Life Sciences from a “sector perform” rating to an “outperform” rating and raised their target price for the stock from $9.00 to $27.00 in a research note on Monday, December 8th. Cantor Fitzgerald upped their price target on WAVE Life Sciences from $34.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. B. Riley Financial increased their price target on WAVE Life Sciences from $19.00 to $37.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, Bank of America started coverage on shares of WAVE Life Sciences in a report on Thursday, February 5th. They issued a “buy” rating and a $38.00 price objective on the stock. Fourteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, WAVE Life Sciences presently has an average rating of “Moderate Buy” and an average price target of $32.56.

Institutional Investors Weigh In On WAVE Life Sciences

A number of institutional investors have recently modified their holdings of WVE. GSK plc acquired a new position in WAVE Life Sciences during the 4th quarter worth about $310,177,000. Federated Hermes Inc. increased its stake in WAVE Life Sciences by 678,144.7% during the third quarter. Federated Hermes Inc. now owns 3,750,693 shares of the company’s stock worth $27,455,000 after purchasing an additional 3,750,140 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in shares of WAVE Life Sciences by 20.0% during the second quarter. Adage Capital Partners GP L.L.C. now owns 15,016,500 shares of the company’s stock worth $97,607,000 after purchasing an additional 2,500,000 shares in the last quarter. Primecap Management Co. CA boosted its stake in shares of WAVE Life Sciences by 115.7% in the fourth quarter. Primecap Management Co. CA now owns 4,095,282 shares of the company’s stock valued at $69,620,000 after purchasing an additional 2,196,632 shares during the period. Finally, Loomis Sayles & Co. L P boosted its stake in shares of WAVE Life Sciences by 35.3% in the second quarter. Loomis Sayles & Co. L P now owns 3,295,700 shares of the company’s stock valued at $21,422,000 after purchasing an additional 859,160 shares during the period. 89.73% of the stock is owned by institutional investors and hedge funds.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.